Aarti Drugs Limited has announced an interim dividend of ₹2 per share for its shareholders, with the board of directors declaring the dividend at their meeting held on February 3, 2026. The company has set February 9, 2026 as the record date for determining eligible shareholders.

Dividend Declaration Details

The pharmaceutical company's board approved the interim dividend payment of ₹2 per equity share of ₹10 each, representing a 20% dividend for the financial year 2025-26. This dividend distribution demonstrates the company's commitment to returning value to its investor base.

Record Date and Compliance

As per Regulation 42(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Monday, February 9, 2026 has been fixed as the record date for the interim dividend payment. Shareholders holding shares on this date will be eligible to receive the dividend.

The company has informed both BSE Limited and National Stock Exchange of India Limited about this dividend declaration, maintaining compliance with regulatory requirements under Regulation 42(1)(a) and Regulation 43 of SEBI LODR Regulations, 2015.

Shareholder Benefits

The interim dividend announcement provides immediate returns to shareholders without waiting for the annual dividend declaration. This approach allows Aarti Drugs Limited to distribute profits as they are generated, providing regular income streams to investors and reflecting the company's financial stability and cash flow generation capabilities.

Aarti Drugs Limited announced that CRISIL Limited has reaffirmed the company's credit ratings on its bank facilities, maintaining confidence in the pharmaceutical manufacturer's financial stability. The rating agency confirmed its assessment of the company's creditworthiness across facilities totaling Rs. 1,768 crores.

Credit Rating Details

CRISIL Limited reaffirmed both long-term and short-term credit ratings for Aarti Drugs Limited's banking facilities. The comprehensive rating covers the company's diverse financing arrangements across multiple banking partners.

Banking Partner Distribution

The rated facilities are distributed across 16 different banking institutions, demonstrating the company's diversified financing approach. Major banking partners include HDFC Bank Limited with facilities worth Rs. 300 crores across cash credit and working capital arrangements, Kotak Mahindra Bank Limited providing Rs. 433.13 crores through term loans and working capital facilities, and Axis Bank Limited contributing Rs. 225 crores in working capital facilities.

Key Banking Relationships

• HDFC Bank Limited: Rs. 300 crores (Cash Credit: Rs. 64 crores, Working Capital: Rs. 236 crores)
• Kotak Mahindra Bank Limited: Rs. 433.13 crores (Term Loan: Rs. 253.13 crores, Working Capital: Rs. 180 crores)
• Axis Bank Limited: Rs. 225 crores (Working Capital Facility)
• Proposed Working Capital Facility: Rs. 124.87 crores

Other significant banking partners include Standard Chartered Bank, Emirates NBD Bank PJSC, The Hongkong and Shanghai Banking Corporation Limited, Sumitomo Mitsui Banking Corporation, State Bank of India, Union Bank of India, RBL Bank Limited, DBS Bank Limited, and IDBI Bank Limited.

Regulatory Compliance

The company communicated this development to BSE Limited and National Stock Exchange of India Limited on January 29, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Rushikesh Deole signed the regulatory filing, ensuring proper disclosure to stakeholders.

The rating letter from CRISIL remains valid until March 31, 2026, with the rating agency maintaining continuous surveillance over the company's facilities. CRISIL noted that any proposed facilities not availed within 180 days from January 29, 2026, would require fresh revalidation.